EXERCISE ON OZEMPIC, WEGOVY, OR MOUNJARO: WHY RESISTANCE-ENGAGING CARDIO MATTERS
On a GLP-1, roughly 25% of weight lost is lean tissue, not fat. The kind of exercise you choose changes how much muscle you keep. This article covers what the body-composition data shows and why resistance-engaging cardio belongs in your routine. This is educational content, not medical advice. Always talk to your doctor before starting a new exercise routine.
GLP-1 medications, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), are working. In Gallup's mid-2025 polling, 12.4% of US adults reported taking a GLP-1 for weight loss, more than double the 5.8% rate from early 2024. The clinical trial results are the reason: STEP-1 patients on semaglutide lost an average of 14.9% of body weight over 68 weeks (Wilding et al., NEJM 2021). SURMOUNT-1 patients on the highest dose of tirzepatide lost 20.9% over 72 weeks (Jastreboff et al., NEJM 2022). Those are numbers that historically required bariatric surgery.
But the scale only tells part of the story. What the scale doesn't show, what tissue you're losing along with the fat, is where exercise comes in. And not just any exercise.
What Happens to Your Muscles on a GLP-1?
Weight lost on a GLP-1 is not uniformly fat. Published DXA body-composition substudies have quantified the split, and the pattern holds across drug, dose, and population.
In the STEP-1 DXA substudy (n=140, semaglutide 2.4 mg, 68 weeks), participants lost 15.0% of total body weight on average. Of that, fat mass dropped 19.3% and visceral fat dropped 27.4%, good news. But lean body mass also dropped 9.7% in absolute terms (Wilding et al., Diabetes Obes Metab 2021). The proportion of lean mass to total body mass actually improved slightly, because fat was lost faster than lean, but in absolute terms, nearly 10% of the body's lean tissue was gone.
The SURMOUNT-1 body-composition substudy (tirzepatide, 72 weeks) found the same pattern at a larger magnitude. Total weight: -21.3%. Fat mass: -33.9%. Lean mass: -10.9%. Roughly 75% of the weight lost was fat, 25% was lean tissue, in both the drug arms and the placebo arm, and consistent across age, sex, and weight-loss subgroups (Look et al., Diabetes Obes Metab 2025).
The SELECT trial (semaglutide in cardiovascular patients, n=17,604) added another data point: about a third of the 20% MACE reduction was mediated by waist-circumference change, with a 4% lower MACE risk per 5 cm reduction (Lincoff et al., NEJM 2023; SELECT body-composition subanalysis, 2025). The cardiovascular benefits are real, but they travel alongside lean-tissue changes that also deserve attention.
A 2024 review in Diabetes, Obesity and Metabolism adds useful context: "lean body mass" on DXA includes organs, bone, and water, not just skeletal muscle. Some MRI-based work suggests muscle quality can improve (less fat infiltration, better insulin sensitivity) even as volume drops. The research, in other words, is nuanced. But the headline finding, meaningful lean-tissue loss alongside fat loss, is consistent across trials.
And importantly, this ~25% lean-mass share of weight loss is similar to what happens with caloric restriction alone (Weinheimer et al., 2010 systematic review of 52 studies). GLP-1s aren't uniquely bad for muscle. Losing weight is what's hard on muscle. The question is what you do about it.
Why Does Muscle Loss Matter Beyond the Mirror?
Skeletal muscle is metabolically and structurally load-bearing, not just aesthetic. The consequences of losing it become obvious when you lose a lot of it quickly.
- Resting metabolic rate. Muscle is more metabolically active than fat at rest. Less muscle means a lower floor on daily calorie burn, which compounds over years and makes weight maintenance harder after the medication or the deficit ends.
- Bone density. In the Villareal NEJM 2017 trial of obese older adults losing weight, the aerobic-only group lost roughly 3% of hip BMD over 26 weeks. The resistance-training groups lost far less (Villareal et al., NEJM 2017). Rapid weight loss without loading is hard on bone.
- Functional capacity. Getting up off the floor, carrying groceries, climbing stairs, these draw on lower-body and posterior-chain strength. Losing that capacity in your 40s or 50s has a long tail.
- Long-term maintenance. The more muscle mass you preserve, the better your chances of keeping weight off if you cycle off the medication. That's mechanical, more muscle, higher daily expenditure, more wiggle room on intake.
This is why the major guideline bodies have moved quickly. The American Diabetes Association's 2025 Standards of Care explicitly emphasize meeting resistance-training guidelines and adequate protein intake for patients on weight-management pharmacotherapy. The WHO's first-ever GLP-1 guideline (December 2025) includes a conditional recommendation that structured physical activity accompany GLP-1 pharmacotherapy. The EASO (European Association for the Study of Obesity) working group recommends 200-300 minutes per week of aerobic activity plus moderate-to-high-intensity resistance training for people managing obesity.
None of them are optional add-ons anymore. Structured, resistance-loaded exercise is part of the standard of care.
What Does the Research Say About Exercise During GLP-1 Weight Loss?
Resistance-loaded exercise preserves more lean mass during a deficit than low-load cardio alone. Here's what the controlled trials show.
The best-controlled evidence points in one direction: some form of resistance loading, whether pure strength training or a resistance-engaging cardio modality, outperforms pure low-load cardio.
- Villareal et al., NEJM 2017 randomized 160 obese older adults to 26 weeks of weight loss plus exercise. The aerobic-only group lost 5% of lean mass. The resistance-only group lost only 2%. The combined aerobic + resistance group lost 3% but showed the biggest functional gains (physical performance test +21%). Conclusion: combined training best preserved function during weight loss.
- Longland et al., AJCN 2016 compared higher protein (2.4 g/kg/day) versus moderate protein (1.2 g/kg/day) in young men during a 4-week deficit with resistance training and HIIT six days per week. The high-protein group gained 1.2 kg of lean mass while in a deficit; the control group held steady. Protein intake matters alongside the training stimulus.
- Weinheimer et al., 2010, a systematic review of 52 studies in adults 50+, found that energy restriction alone led to substantial fat-free-mass loss in the majority of studies reviewed, and that adding exercise roughly halved the rate of excess lean-mass loss.
- Murphy & Koehler, Scand J Med Sci Sports 2022 reviewed resistance-trained athletes in caloric deficits and found that maintaining resistance-training volume during a deficit protects lean mass, programs with a sustained training stimulus outperformed reduced-volume approaches.
The pattern is hard to miss: medication handles the deficit, exercise protects the tissue and improves metabolic quality.
Why Does Rowing Fit the GLP-1 Use Case?
Here's where the evidence stops and the reasoning starts. There is no RCT directly comparing rowing to treadmill walking, cycling, or dedicated strength training in a GLP-1 cohort. So the case for rowing is a mechanism-stacking argument, not a head-to-head claim. With that caveat in place:
1. A rowing stroke is roughly 60% legs, 30% core, 10% arms. Every stroke loads the posterior chain, glutes, hamstrings, spinal erectors, lats, under resistance. That's different from cycling (quad-dominant, low external load) or treadmill walking (mostly bodyweight cardio). Rowing doesn't replace heavy compound lifting, but its resistance component is substantially higher than typical steady-state cardio, which makes it a more muscle-engaging option for people who won't or can't add a separate strength program right away.
2. It's low-impact. GLP-1 users often enter exercise deconditioned and at higher BMI, and body weight can change quickly. Rowing is non-weight-bearing at the impact level, no ground reaction forces pounding through knees and hips. That aligns with the ACSM's 2024 position on physical activity in medical weight management, which emphasizes progressive, individualized programming for deconditioned starters.
3. It's scalable. On an air-and-magnetic resistance rower, the intensity is set by how hard you pull. A deconditioned beginner can row gently at 2 out of 10 on the first week. Four months in, the same machine is still challenging. That matters during a multi-year body-composition project.
4. It's efficient. A rowing stroke recruits a large amount of muscle mass simultaneously, producing a high VO2 demand in a short window. GLP-1 fatigue, especially in the dose-escalation weeks, is real. When you have twenty good minutes, a modality that delivers full-body work in that window is practical.
5. It's accessible for people who haven't exercised in years. The seated, self-paced stroke, the fact that you can stop whenever, and the ability to row at a conversational pace all lower the activation energy. Many GLP-1 patients are returning to exercise after a long gap.
What this article will not claim: that rowing uniquely prevents GLP-1 muscle loss, that it outperforms dedicated resistance training for hypertrophy, or that it's clinically recommended over other modalities. None of those claims have RCT support. What rowing does offer is a low-impact, full-body, resistance-engaging cardio modality that checks more of the muscle-preservation boxes than treadmill walking or cycling alone, and that many people find sustainable.
What Are Other Fitness Brands Saying About GLP-1 Exercise?
Aviron isn't first to this conversation. Hydrow has two GLP-1-specific articles (one on combating muscle loss, one a user testimonial). NordicTrack has the most aggressive content program in the category, with five articles covering GLP-1 and strength training, GLP-1 fatigue management, and nutrition. iFit has launched a coached "GLP-1 Strength Support Series." Tonal is positioning itself as the muscle-preservation answer to GLP-1 weight loss in its 2026 predictions content.
The fact that the equipment category has moved on this reflects a real demand: people on GLP-1s are looking for exercise guidance, and they're looking for it in the places they buy equipment. This article is Aviron's entry into that conversation, built on the angle we think is underserved, resistance-engaging cardio specifically, low-impact enough for deconditioned starters, scalable enough to grow into.
Which Rowing Machine Should You Use on a GLP-1?
The Strong Series Rower is built for the multi-year body-composition project a GLP-1 protocol demands. Here's what matters for this use case. The Strong Series Rower is $1,999 with a 30-day trial and $29/month family membership (unlimited profiles, relevant because if you're on a GLP-1, it's fairly common that someone else in the household is also trying to get healthier, and adding a second, third, or fourth profile doesn't cost extra).
Specs that matter for the GLP-1 use case:
- Dual air + magnetic resistance up to 100 lbs, every stroke is genuinely loaded, and the intensity scales with effort.
- 86% of muscles engaged per stroke, full-body work, useful when your workout window is short.
- 507 lb weight capacity, fits users up to 6'8", accessible for a wide range of body sizes, including people starting at higher weights.
- Over 1,000 workouts including coached classes, fitness entertainment games, scenic rows, and multiplayer, not gimmicks, just enough variety to show up on days when motivation is thin. The platform has delivered 4M+ workouts to 50K+ members, with a 92% one-year retention rate, which is the number we watch most closely, because equipment you don't use doesn't preserve anything.
- Rotating HD touchscreen with Netflix, Disney+, HBO Max, Spotify, and more, row while you watch, if that's what it takes.
- 20-year warranty on frame, parts, and electronics while membership is active, this is a multi-year body-composition project, and the equipment needs to last as long as the project does.
- Standard free shipping across the contiguous US and Canada, financing, HSA/FSA eligibility, and a 30-day in-home trial.
This is not a pitch that rowing on an Aviron will prevent GLP-1 muscle loss. The honest version is: if you're adding a resistance-engaging cardio modality to your routine while on a GLP-1, this is a credible piece of equipment to do it on, with a trial window that lets you find out whether rowing actually fits your life before committing.
What Should You Know Before You Start?
Before you row a single meter, a few things worth saying plainly:
- This is not medical advice, and GLP-1s are a medical tool. Talk to your doctor or prescribing clinician before starting any exercise program, especially in the first weeks of starting or dose-escalating. They know your cardiovascular history, your medication interactions, and your baseline.
- Side effects are real. Nausea, fatigue, and reduced appetite, particularly during dose escalations, can make workouts harder. Start conservatively. Short, easy sessions that you actually complete beat ambitious sessions that you skip.
- Hydration and protein matter. Adequate protein intake is consistently flagged by the ADA, EASO, and joint advisories (ACLM/ASN/OMA/TOS, AJCN/Obesity 2025) as a foundational support for lean-mass preservation during weight loss. Your clinician or a registered dietitian can personalize the target.
- Rowing has a learning curve. The first two weeks feel awkward. Form matters, legs, then back, then arms on the drive; arms, then back, then legs on the recovery. Use the onboarding content.
- This is about what you keep, not what you lose. Nothing in this article is a weight-loss claim. The medication does the weight loss. Exercise is about body composition, function, bone, and metabolic quality, the things the scale doesn't measure.
Ready to row?
If you're on a GLP-1 and ready to add resistance-engaging cardio to your routine, the Strong Series Rower is $1,999 with a 30-day trial, enough time to know whether rowing fits your life before you commit. The $29/month family membership covers unlimited profiles, which matters if more than one person in the household is working on their health.
Talk to your doctor first. Then start slow. Then show up.
Related reading
- The Complete Beginner's Guide to Using a Rowing Machine, start here if you've never used a rower before.
- What Muscles Does a Rowing Machine Work?, the biomechanics behind the 86%-per-stroke claim.
- 15 Rowing Machine Benefits, the broader case for rowing as a primary modality.
- Rowing Machine Nutrition, including protein intake guidance for preserving lean mass.
Citations
- Wilding JPH et al. NEJM 2021, STEP-1 semaglutide trial.
- Wilding JPH et al. Diabetes Obes Metab 2021, STEP-1 DXA body-composition substudy.
- Jastreboff AM et al. NEJM 2022, SURMOUNT-1 tirzepatide trial.
- Look et al. Diabetes Obes Metab 2025, SURMOUNT-1 body-composition substudy.
- Lincoff AM et al. NEJM 2023, SELECT cardiovascular outcomes trial; SELECT body-composition subanalysis 2025.
- Villareal DT et al. NEJM 2017, aerobic vs. resistance vs. combined training in obese older adults.
- Longland TM et al. AJCN 2016, higher protein + resistance training during energy deficit.
- Weinheimer EM et al. 2010, systematic review of energy restriction +/- exercise on fat-free mass.
- Murphy CH & Koehler K. Scand J Med Sci Sports 2022, resistance training for lean-mass sparing.
- Lundgren JR et al. NEJM 2021, S-LITE trial: liraglutide + exercise after low-calorie diet; and Cardiovasc Diabetol 2023 MetS substudy.
- ADA Standards of Care in Diabetes 2025; WHO Global Guideline on GLP-1 Medicines for Obesity, December 2025; ACSM 2024 position on physical activity in medical weight management; EASO Physical Activity Working Group clinician recommendations.
Aviron is a fitness equipment company, not a medical provider. This article is educational. Talk to your doctor about whether GLP-1 medications and any new exercise program are right for you.
